Melanoma: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner
Lisa Kottschade, APRN, MSN, CNP
J Adv Pract Oncol 2021;12(6):594-598 |
© 2021 Harborside™
With coverage from The ASCO Post, Lisa Kottschade, APRN, MSN, CNP, of Mayo Clinic, reviews data on immune therapy after surgery, the combination of the anti–LAG-3 antibody relatlimab and nivolumab, and a 6.5-year update of combination nivolumab and ipilimumab.
For access to the full length article, please sign in